Filtered By:
Condition: Hypertension
Therapy: Dialysis

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 145 results found since Jan 2013.

Difficulty of stroke management in the dialysis child
ConclusionCause or consequences of the renal disease, HT must be properly treated in order to reach the recommended targeted blood pressure values. The time required to take charge the hypertensive stroke determines the prognosis. The challenge is to optimize the health care sector to reduce mortality and sequelae.
Source: Archives of Cardiovascular Diseases Supplements - July 24, 2019 Category: Cardiology Source Type: research

Prevention and treatment of stroke in patients with chronic kidney disease: an overview of evidence and current guidelines
Chronic Kidney Disease (CKD) is strongly associated with an increased risk of stroke, small vessel disease, and vascular dementia. Common vascular factors for stroke, such as hypertension, diabetes, and atrial fibrillation, are more prevalent in CKD patients, accounting for this association. However, factors unique to these patients, such as uraemia, oxidative stress, mineral and bone abnormalities, as well as dialysis-related factors are also believed to contribute to risk. Despite improvements in stroke treatment and survival in the general population, the rate of improvement in patients with CKD, especially those who ar...
Source: Kidney International - October 17, 2019 Category: Urology & Nephrology Authors: Dearbhla M. Kelly, Peter M. Rothwell Tags: Review Source Type: research

Neurological Involvement in Primary Systemic Vasculitis
Conclusion Neurological involvement is a common complication of PSV (Table 1), and neurologists play an important role in the identification and diagnosis of PSV patients with otherwise unexplained neurological symptoms as their chief complaint. This article summarizes the neurological manifestations of PSV and hopes to improve neuroscientists' understanding of this broad range of diseases. TABLE 1 Table 1. Common CNS and PNS involvements of primary systemic vasculitis. Author Contributions SZ conceived the article and wrote the manuscript. DY and GT reviewed and edited the manuscript. All authors ...
Source: Frontiers in Neurology - April 25, 2019 Category: Neurology Source Type: research

Hypertension - human studies
Conclusions:Higher predialysis SBP variability is associated with stroke on HD populations suggesting a potential role for cerebral perfusion instability. We confirm known associations between age, diabetes, pre-existent cerebrovascular disease and hypertension. In contrast to studies in non-dialysis patients we do not find an association between EPO dose and stroke. Interventional trials of blood pressure management on stroke are recommended.
Source: Nephrology Dialysis Transplantation - May 10, 2013 Category: Urology & Nephrology Authors: Power, A., Duncan, N., Pusey, C., Usvyat, L., Marcelli, D., Marelli, C., Kotanko, P., MONDO Consortium, Li, Z., Wang, J., Yuan, X., Wang, J., Wang, L., Ozkayar, N., Altun, B., Yildirim, T., Yilmaz, R., Dede, F., Hayran, M., Arici, M., Aki, T., Erdem, Y., Tags: Abstracts Source Type: research

Can I use DOAC in a patient with renal disease?
Case A 76-year-old man is diagnosed with non-valvular atrial fibrillation. His comorbid conditions are hypertension, diabetes complicated by neuropathy, and chronic kidney disease stage 3. His current medications include metformin, lisinopril, gabapentin, and aspirin. His most recent laboratories showed a creatinine 1.8, creatinine clearance (CrCl) 35 mL/min, hemoglobin 11g/dL, and international normalized ratio 1.0. His congestive heart failure, hypertension, age, diabetes, stroke, vascular disease, and sex (CHADSVASc) score is 4. Which medication should we use to prevent stroke in this patient?  Brief overview of the is...
Source: The Hospitalist - February 3, 2022 Category: Hospital Management Authors: Ronda Whitaker Tags: Renal & Genitourinary Source Type: research

New XARELTO ® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020
RARITAN, N.J., November 9, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that 10 data presentations will be shared at the virtual American Heart Association (AHA) Scientific Sessions 2020 from November 13-17. Most notably, four new sub-analyses of XARELTO® (rivaroxaban) from the landmark VOYAGER PAD trial, part of the EXPLORER global cardiovascular research program, will be presented, including two live, featured science oral presentations. “We're pleased VOYAGER PAD was selected to be front and center once again at a major medical congress, as there's an urgent need for data in ...
Source: Johnson and Johnson - November 9, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Valvular calcification upon initiating dialysis predict the appearance of cardiovascular events in patient evolution.
CONCLUSIONS: The prevalence of VC at the commencement of dialysis is very high and its presence is an independent predictor of event and cardiovascular mortality presentation in the course of follow-up. PMID: 26300509 [PubMed - as supplied by publisher]
Source: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia - August 25, 2015 Category: Urology & Nephrology Tags: Nefrologia Source Type: research

Cost-Effectiveness of Statins for Primary Cardiovascular Prevention in Chronic Kidney Disease
ConclusionsAlthough statins reduce absolute CVD risk in patients with CKD, the increased risk of rhabdomyolysis, and competing risks associated with progressive CKD, partly offset these gains. Low-cost generic statins appear cost-effective for primary prevention of CVD in patients with mild-to-moderate CKD and hypertension.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - March 18, 2013 Category: Cardiology Source Type: research

Renal physiology and kidney stones
Conclusions: The occurrence of a kidney stone is associated with an increased risk of cardiovascular events including AMI, death due to CHD,PTCA/CABG and stroke. These data suggest that people with a clinically recognized kidney stone should be followed more closely to evaluate for the possibility of subsequent cardiovascular events -- younger people and women.
Source: Nephrology Dialysis Transplantation - May 10, 2013 Category: Urology & Nephrology Authors: Alexander, R. T., Samuel, S., Wiebe, N., Bello, A., Klarenbach, S., Curhan, G. C., Tonelli, M., Hemmelgarn, B., Mingione, A., Terranegra, A., Aloia, A., Arcidiacono, T., Brasacchio, C., Hou, J., Dell'Antonio, G., Vezzoli, G., Soldati, L., Shimizu, T., Has Tags: Abstracts Source Type: research

Is long-term paracetamol use not as safe as we thought?
Conclusion This is a valuable review that has searched the literature and identified eight observational studies in adults that have looked at the adverse effects that may be associated with paracetamol use. As the researchers say, it will add to information on the potential harms of paracetamol – an area where up-to-date information has been lacking. The studies included very large population sizes, and collectively provide some evidence suggesting potential effects upon the cardiovascular system, kidney and gastrointestinal system. There was also a suggestion of increased risk of all-cause mortality. However, it is v...
Source: NHS News Feed - March 3, 2015 Category: Consumer Health News Tags: Heart/lungs Medication Source Type: news

Visit-to-visit blood pressure variability is a risk factor for all-cause mortality and cardiovascular disease: a systematic review and meta-analysis
Conclusion: In summary, among the wide heterogenetic population, modest associations between VVV of SBP and all-cause mortality, CVD incidence, CVD mortality, CHD incidence, and stroke incidence were found. Findings of the current study suggested that standardized approaches of monitoring VVV in the high-risk population, including patients with cardiac infarction, diabetes, stroke, and patients with chronic kidney disease or in dialysis, are necessary in designing a prospective clinical study on the association of VVV and patients’ prognosis.
Source: Journal of Hypertension - December 1, 2016 Category: Cardiology Tags: Reviews Source Type: research

Direct oral anticoagulants in chronic kidney disease: an update
Purpose of review Direct oral anticoagulants (DOACs) are variably eliminated by the kidneys rendering their use potentially problematic in patients with chronic kidney disease (CKD) or necessitating appropriate dose adjustment. Recent findings Both observational and limited randomized trial data for DOACs compared with no treatment or with warfarin for patients with atrial fibrillation on maintenance dialysis were recently published. In a randomized trial in patients on hemodialysis, there was no significant difference in vascular calcification between patients who received rivaroxaban with or without vitamin K2 or vi...
Source: Current Opinion in Nephrology and Hypertension - August 1, 2020 Category: Urology & Nephrology Tags: PHARMACOLOGY AND THERAPEUTICS: Edited by Sankar D. Navaneethan Source Type: research

Branch-first continuous perfusion aortic arch replacement. Insight into our results
CONCLUSIONS: BF-CPAR is safe and adds to the armamentarium of Aortic Arch Repair. In elective and uncomplicated acute-dissection cases, it has no mortality and low stroke (1.9%), and vital organ dysfunction risk. Its results which are comparable to many of the best currently reported series, is driven by avoidance of cerebral circulatory arrest and reduction of cardiac and visceral ischemic time.PMID:35238522 | DOI:10.23736/S0021-9509.22.12272-X
Source: The Journal of Cardiovascular Surgery - March 3, 2022 Category: Cardiovascular & Thoracic Surgery Authors: George Matalanis Varun J Sharma Source Type: research